The Copay Fairness for Veterans Act (HR 1644) eliminates out-of-pocket costs for veterans receiving preventive health services through the Department of Veterans Affairs (VA). It removes copayments for medications and hospital care related to preventive services, including evidence-based items rated A/B by the U.S. Preventive Services Task Force, CDC-recommended immunizations, and women's preventive care like contraceptives and screenings under specific guidelines. The bill directly affects veterans using VA healthcare for these preventive services, ensuring they pay nothing for covered care. It amends existing VA law to define "preventive health services" broadly and removes financial barriers for these specific health interventions.
HR 3493, the Global Fairness in Drug Pricing Act, requires the U.S. Health and Human Services Secretary to establish price targets for pharmaceutical manufacturers, ensuring U.S. drug prices align with those in comparable developed countries. It directs the HHS Secretary to certify safe importation of drugs from low-cost countries and facilitate direct-to-consumer purchasing programs at the set prices. The bill also authorizes antitrust enforcement against drug companies for anticompetitive practices and mandates a study on whether manufacturers engage in unfair pricing that forces U.S. patients to subsidize global drug research. This legislation directly affects pharmaceutical manufacturers and American patients seeking affordable prescription drugs.
HR 1901, the CHIPP Act, makes Children's Health Insurance Program (CHIP) funding permanent for all future fiscal years, removing previous expiration dates that required annual congressional renewal. This directly affects low-income children and families who rely on CHIP coverage and the states that administer these programs. The key mechanism is amending federal law to require "such sums as are necessary" for CHIP funding starting in fiscal year 2029 and beyond. Other provisions adjust funding for related programs like pediatric quality measures and outreach, but the primary change is CHIP’s permanent funding structure.
The Stop CMV Act of 2025 requires hospitals to screen all infants under 21 days old for congenital cytomegalovirus (CMV), a virus that can cause hearing loss and developmental delays. States must establish screening standards - including parent notification - within two years of the law’s enactment, or the federal Advisory Committee on Heritable Disorders will set them. The bill provides federal grants for states to implement screening, improve data systems, and fund research on CMV prevention, diagnostics, and treatments through the CDC and NIH.
The Patient Fairness Act of 2025 increases Health Savings Account (HSA) contribution limits and removes restrictions on how funds can be used. It raises the annual limit to $8,000 for individuals (or $16,000 for married couples) plus $3,000 per dependent, and allows those 55 or older to contribute an additional $3,000 (or $6,000 for couples). The bill also permits transferring HSA funds to relatives within 60 days after the account holder’s death without penalty. Additionally, it codifies existing hospital price transparency rules, requiring healthcare facilities to publish standard service prices permanently.
HR 1476, the PLASMA Act, adjusts discount rates for plasma-derived drugs under Medicare Part D starting in 2026. It sets gradually decreasing discount percentages (from 99% down to 90% by 2030) for these specific drugs when beneficiaries reach their annual out-of-pocket spending threshold. The bill directly affects Medicare Part D beneficiaries using plasma-derived biological products (drugs made from human blood or plasma) and the manufacturers of those drugs. Certain drugs for low-income subsidy beneficiaries and small manufacturers are excluded from these discount provisions. The law phases in these changes over several years to align with existing Medicare Part D cost-sharing rules.
HR 3503, the Kidney Donation Anti-Discrimination Act, prohibits life insurance companies from discriminating against living kidney donors in policy terms (such as price, coverage, or cancellation) solely based on their donation status. It requires insurers to show evidence of actual health risks unrelated to the donation before charging higher premiums or denying coverage. Individuals harmed by such discrimination can sue insurers in federal court for damages and legal fees. The law also ensures states can offer stronger protections to living kidney donors than this federal standard provides.
HR 2656, the *Removing Nitrate and Arsenic in Drinking Water Act*, establishes a federal grant program to help community water systems, schools, and other facilities reduce harmful nitrate and arsenic levels in drinking water. Eligible entities like municipalities, nonprofits, and water systems can apply for grants to install treatment technology, with priority given to disadvantaged communities, areas with past non-compliance, and facilities serving children or vulnerable populations. The program authorizes $15 million annually starting in 2026, limiting administrative costs to 4% of funds. It requires applicants to identify contamination sources and demonstrate how their project will reduce contaminants, aiming to improve water safety for at-risk communities.
HR 3665, the Medicare Economic Security Solutions Act, modifies Medicare Part B late enrollment penalties. It increases the penalty rate from 10% to 15% of the monthly premium but limits the penalty period to twice the original 12-month intervals. The bill also excludes months with COBRA, retiree, or VA coverage from counting toward the penalty and creates a special enrollment period for people whose COBRA or retiree coverage ends. These changes directly affect Medicare Part B enrollees who had gaps in coverage due to employment transitions or other qualifying circumstances.
This bill prohibits U.S. foreign aid from funding any foreign government or organization that provides, promotes, or facilitates abortions under most circumstances. It blocks funding to foreign entities performing abortions, offering abortion referrals, promoting abortion services, or funding related research, with exceptions only for pregnancies resulting from rape or incest (requiring documented proof like police reports). Foreign governments and organizations receiving U.S. aid must certify compliance annually, and violations risk losing future funding, repayment of misused funds, or penalties. The policy directly affects U.S. foreign assistance programs targeting global health and development, excluding only rape/incest cases with required documentation.